Intergrated drug discovery
Selcia Discovery has all the capabilities required to discover a prototype compound acting on your target and to transform this chemical starting point into a drug candidate with a solid chance of success.
Lead Discovery
If you have a target for which you seek a chemical lead, we can use our proprietary fragment screening platform to generate chemical starting points for optimisation. Our assay development and screening group will verify functional activity, ensuring that only quality leads enter the optimisation process. We also offer to screen customer’s compounds or libraries in our CE screen.
Lead optimisation
IIf you already have a chemical starting point and seek to transform it into a drug candidate, Selcia can assist you in designing a comprehensive program to ensure fast lead optimisation. In addition to Selcia’s chemistry expertise, we can provide help with assay development and screening of compounds to ensure a fast turnaround of results. We also have supporting ADME capabilities to optimise good drug properties at an early stage. In addition Selcia can manage mutually agreed subcontracted services (e.g. pharmacokinetics, toxicology, etc.). All the intellectual property generated during the project belongs to the customer and we work with your IP department to ensure the best possible protection of your intellectual property. The product we aim to deliver is a robust candidate for clinical development with strong patent coverage.
Fast track your project from discovery to clinical candidate
Clive Cornell, Divisional Head Discovery
MedChemPlus Projects
Selcia has a few selected projects available for partnerships. In this type of project we offer a package consisting of non-optimised proprietary compounds plus biological activity and intellectual property. MedChemPlus projects are offered as a collaborative project. In return for research funding during the lead optimisation phase the customer gets exclusive and comprehensive worldwide rights to manufacture and sell the resulting products. Deal structures typically involve funding of ongoing research, milestone payments, and royalties on sales. As in lead optimisation, the product delivered to the customer is a robust candidate for clinical development.
Details of such projects are only disclosed under CDA.